Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
about
Addition of pamidronate to chemotherapy for the treatment of osteosarcomaBone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaZoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.Direct antitumour activity of zoledronic acid: preclinical and clinical data.Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels.The off-label use of targeted therapies in sarcomas: the OUTC'S programThe combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.The Current and Future Therapies for Human Osteosarcoma.Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer modelFeasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupPast, present and future of therapies in pediatric sarcomas.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.Zoledronic acid and irradiation in oral squamous cell carcinoma.Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors.Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.
P2860
Q24594269-BD7D6919-91E0-4F13-99B5-1F196F6BD4EDQ26771376-9BC34912-524F-44CD-B227-97D52684F989Q33273281-B171D761-096A-4EBC-8BE9-B78F4661539FQ33850938-413DCC47-23D0-4957-B29D-EABA0099CC21Q34631306-BA48AE28-9490-45D5-A4AC-5CE21DBAA4DFQ34653709-520A0640-2BC9-4F2B-9697-4338D8CB0498Q34897996-675C82CB-511D-4DA6-A39D-CF1761BFE9F5Q35653799-A82D42DF-87F0-4CA5-BA4D-AC29A2773B8FQ36034236-E8406A6E-988A-4F04-9803-AC063CBA3CDDQ36514299-4D6DAFAA-01C6-4026-B90B-E51DED144108Q36847530-CB6A0D66-01EE-4C15-9FCC-BBBEF80D61A2Q36946864-96178B4A-979E-4B2E-8C14-783F3B571271Q37725915-65186587-9BCF-4BD8-A081-9A713331FBF1Q38247428-08EB7017-5B2C-4F19-A572-3285D4F82577Q38624909-BB67F612-D52D-4DC2-AEEC-9394BCCF1B41Q38730126-D3085F9C-C767-4DF3-867A-1BC16A9A0FD2Q38971985-43D7DFFF-7309-49B7-BCC5-89345A424C52Q39466674-4C4FD5F9-7790-4649-AE3E-C2F5209C50AEQ41143144-36D368E7-A79C-416F-BC9E-C6CCBCD380DCQ42634367-DCA1F48A-70D9-414B-968D-F1CCB06D96C5
P2860
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combined effects of a third-ge ...... s against murine osteosarcoma.
@en
Combined effects of a third-ge ...... s against murine osteosarcoma.
@nl
type
label
Combined effects of a third-ge ...... s against murine osteosarcoma.
@en
Combined effects of a third-ge ...... s against murine osteosarcoma.
@nl
prefLabel
Combined effects of a third-ge ...... s against murine osteosarcoma.
@en
Combined effects of a third-ge ...... s against murine osteosarcoma.
@nl
P2093
P2860
P356
P1476
Combined effects of a third-ge ...... s against murine osteosarcoma.
@en
P2093
H Takeshita
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603548
P407
P577
2007-01-01T00:00:00Z